Blueprint Medicines Corp. (BPMC)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Blueprint Medicines (BPMC) Stock Jumps 18.2%: Will It Continue to Soar?
Blueprint Medicines (BPMC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Blueprint Medicines price target lowered by $11 at Wedbush, here's why
Blueprint Medicines -3.19 (-3.52%) Celldex -2.21 (-8.33%)
Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue?
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?
Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs
Blueprint Medicines' core revenue driver, AYVAKIT, has gained traction in systemic mastocytosis and gastrointestinal stromal tumors, reflecting strong market adoption. The recent AYVAKIT expansion into Germany and the potential for further indication of growth underpin Blueprint's valuation and future revenue projections. Blueprint's investigational pipeline, including drugs like BLU-222 and elenestinib, targets various cancers and mast cell disorders, enhancing long-term growth potential.
BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up
Blueprint stock gains from better-than-expected third-quarter results, driven by robust Ayvakit sales growth. The company raises revenue guidance for 2024.
Blueprint Medicines Corporation (BPMC) Q3 2024 Earnings Call Transcript
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Christy Rossi - Chief Operating Officer Mike Landsittel - Chief Financial Officer Fouad Namouni - President-Research & Development Conference Call Participants Marc Frahm - TD Cowen Brad Canino - Stifel Reni Benjamin - Citizens JMP Paul Jeng - Guggenheim Tommie Reerink - Goldman Sachs Derek Archila - Wells Fargo Mike Ulz - Morgan Stanley Ami Fadia - Needham Markus Schweiger - Oppenheimer Peter Lawson - Barclays Laura Prendergast - Raymond James David Lebowitz - Citi Sudan Loganathan - Stephens Operator Good morning. My name is Nadia, and I'll be your conference operator today.
Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates
Blueprint Medicines (BPMC) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $2.20 per share a year ago.
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.
Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Blueprint Medicines (BPMC) Upgraded to Strong Buy: What Does It Mean for the Stock?
Blueprint Medicines (BPMC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Wall Street Analysts Predict a 41.4% Upside in Blueprint Medicines (BPMC): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 41.4% in Blueprint Medicines (BPMC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The Schall Law Firm Has Launched An Inquiry Into Whether Blueprint Medicines Corporation Violated Securities Laws And Impacted Investors Are Invited To Join
LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
